| TOTAL | $31.7M |
| VENTURE FUNDING TOTAL | $31.7M |
| Series B, 1/10 Novartis Venture Fund Pfizer Bay City Capital Life Sciences Partners | €21.7M |
Merus B.V., a biomedical company, engages in the discovery and development of antibody-based biopharmaceuticals. It develops Oligoclonics technology that offers a class of human antibodies, called Oligoclonics. Oligoclonics is a concept whereby a mixture of various human therapeutic antibodies, directed to a common antigen are produced from a single cell clone. The company was founded in 2003 and is based in Driebergen, the Netherlands.
